Stereotaxis (NYSE:STXS), Inc. (NYSE American: STXS), a player in the space of robotic technologies for the treatment of cardiac arrhythmias, has completed the acquisition of Access Point Technologies EP, Inc., a company specializing in the design, manufacture, and commercialization of diagnostic catheters for cardiac ablation procedures.
The acquisition, which was finalized on July 31, 2024, was first announced on May 11, 2024.
The transaction saw Stereotaxis issuing 1,486,620 shares of its common stock as upfront stock consideration for the purchase of all shares of capital stock of Access Point Technologies EP, Inc. from APT Holding Company, Inc.
The strategic move aims to enhance Stereotaxis' product portfolio with Access Point Technologies' range of high-quality diagnostic catheters, which are commercially available in key global markets.
Access Point Technologies, based in Rogers (NYSE:ROG), Minnesota, brings to Stereotaxis its expertise and established presence in the cardiac ablation sector, potentially strengthening Stereotaxis' market position in the electromedical and electrotherapeutic apparatus industry.
Stereotaxis reported a 5% increase in revenue for the first quarter of 2024, reaching $6.9 million, although it also faced an operating loss of $4.7 million and a net loss of $4.5 million for the same period. Stereotaxis expects modest double-digit revenue growth for the full year, not including the expected revenue from the planned acquisition of Advanced Cardiac Therapeutics (APT), which is anticipated to contribute approximately $5 million annually post-closure.
InvestingPro Insights
As Stereotaxis, Inc. (NYSE American: STXS) integrates Access Point Technologies EP into its operations, investors are closely monitoring the company's financial health and stock performance. According to InvestingPro data, Stereotaxis has a market capitalization of $154.39 million, with a high Price / Book ratio of 10.6 as of Q1 2024, signaling that the market values the company's assets quite highly relative to its book value. Despite a slight revenue decline of 2.01% over the last twelve months, the company managed to achieve a quarterly revenue growth of 5.07% in Q1 2024. The gross profit margin stands strong at 55.16%, indicating a robust ability to control costs relative to revenue.
InvestingPro Tips suggest caution, highlighting that the stock has experienced significant volatility and a notable decline over the past week. Analysts are not expecting Stereotaxis to be profitable this year, and the stock does not pay a dividend, which may influence investment decisions for those seeking income. However, the company's liquid assets exceed its short-term obligations, which may provide some stability. For investors seeking more in-depth analysis, there are an additional 7 InvestingPro Tips available, offering valuable insights into Stereotaxis' financials and market performance. These can be accessed through the InvestingPro platform for Stereotaxis at https://www.investing.com/pro/STXS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.